Evaluation of regorafenib in colorectal cancer and GIST
Mené sur 1 052 patients atteints d'un cancer colorectal métastatique en échec thérapeutique (114 centres hospitaliers, 16 pays), cet essai international de phase III évalue le regorafenib du point de vue de la survie globale
Regorafenib is an orally administered multikinase inhibitor. It is administered on a continuous dosing schedule and shows non-specific binding to several intracellular kinases, with potent inhibitory activity against vascular endothelial growth factor receptors 1—3 (VEGFR1 [also known as FLT1 ] , VEGFR2 [KDR ] , and VEGFR3 [FLT4 ] ), PDGFRB, FGFR1, RAF, TIE2, and the mutant oncogenic kinases KIT, RET, and BRAF. Commonly reported ( > 10%) toxic effects include fatigue, hand-foot skin reaction, diarrhoea, ...
The Lancet , commentaire, 2011